ETQ Reliance (Octave Reliance)

Reviewed by the AiGreenTools Editorial Team · Last Updated: June 2026

What the FDA’s QMSR Regulation — Effective February 2, 2026 — Changed for Medical Device QMS

On February 2, 2026, the FDA’s Quality Management System Regulation (QMSR) became effective, replacing 21 CFR Part 820 (the Quality System Regulation) for medical device manufacturers. The change is structurally significant: where Part 820 was an FDA-specific regulation that manufacturers had to translate into their QMS design, QMSR incorporates ISO 13485:2016 by reference — giving that international standard the force of US law and aligning US medical device QMS requirements with the global standard that most international regulatory frameworks already reference.

For medical device manufacturers who had maintained separate quality system documentation for 21 CFR Part 820 (FDA) and ISO 13485 (international), QMSR creates both an opportunity and an obligation: the opportunity to consolidate to a unified global QMS framework, and the obligation to ensure that the QMS now satisfies ISO 13485’s more prescriptive management review, risk management (ISO 14971 alignment), and supplier control requirements — not just the previously sufficient Part 820 provisions.

ETQ Reliance (now transitioning to Octave Reliance) updated its QMS application modules for QMSR alignment before the February 2026 effective date. For medical device manufacturers evaluating QMS platforms in 2026, QMSR compliance is the non-negotiable baseline — not a differentiator — and the question becomes which platform’s QMSR-aligned architecture also satisfies the breadth of quality management requirements across document control, CAPA, supplier quality, and change management that a growing medical device organization needs at multi-site scale.

What Is ETQ Reliance — and Why Is It Being Renamed Octave Reliance?

The core ETQ Reliance / Octave Reliance QMS applications:

• Document Control: Version management, approval routing, controlled distribution, training linkage — 21 CFR Part 11 compliant electronic signatures
• CAPA: Corrective and preventive action with root cause analysis methodology, effectiveness verification, and management review integration
• Audit Management: Audit planning, checklist execution, finding management, and closure verification
• Change Management / Management of Change: Change request, impact assessment, approval chain, and implementation verification — aligned with ISO 13485 Clause 7.3
• Nonconformance Management: NC initiation, product disposition, supplier corrective action requests (SCARs)
• Training Management: Curriculum assignment linked to document revisions, competency matrix tracking, qualification records
• Supplier Quality: Supplier qualification, performance scoring, SCAR management, Approved Supplier List maintenance
• Advanced Analytics + Quality Data Lake: AI-powered trend detection across all QMS records

How Does ETQ Reliance Support FDA 21 CFR Part 11 Compliance?

What 21 CFR Part 11 requires from an electronic QMS:

1. Audit trails: Every electronic record must include a complete, computer-generated, time-stamped history of when and by whom the record was created, modified, or deleted — and what was changed
2. Electronic signatures: Must be unique to the individual, require two distinct identification components (typically user ID + password), include the signed meaning, the date/time, and the full name of the signatory
3. System validation: The software must be validated to ensure it reliably does what it purports to do — under GAMP 5 / CSA (Computer Software Assurance, FDA guidance effective 2022)
4. Access controls: System access must be limited to authorized individuals through appropriate permissions and authentication
5. Record integrity: Electronic records must be protected against modification, destruction, or unauthorized access

ETQ Reliance’s architecture satisfies each of these requirements natively. The audit trail is generated automatically for every record — it cannot be disabled or edited by users. Electronic signatures include all required elements (meaning, name, date/time, unique ID) embedded in the record at the point of signing. The validation documentation package (IQ, OQ, PQ templates) is provided to customers as implementation support materials, aligned with FDA CSA guidance rather than the legacy CSV approach that legacy QMS validation projects used.

For EU pharmaceutical manufacturers subject to GMP Annex 11 (the EU equivalent of 21 CFR Part 11 for computerized systems in pharmaceutical manufacturing), ETQ Reliance’s audit trail, electronic signature, and system validation architecture satisfy the Annex 11 requirements for data integrity, access control, and change control in computerized systems.

What Is the QMSR — and How Does It Affect Medical Device QMS Requirements?

The FDA Quality Management System Regulation (QMSR, 21 CFR Part 820, as revised February 2, 2026) replaced the previous Quality System Regulation by incorporating ISO 13485:2016 by reference. The practical effect: medical device manufacturers must now demonstrate QMS compliance against ISO 13485 requirements, not just the previous Part 820 requirements. Key differences that affect QMS software selection:

• Risk management: ISO 13485 requires documented risk management throughout the product lifecycle — more prescriptive than the previous Part 820 risk approach, and explicitly aligned with ISO 14971 risk management for medical devices
• Management review: ISO 13485 Clause 5.6 specifies detailed management review input and output requirements that Part 820 addressed more broadly
• Design and development: ISO 13485 Clause 7.3 change control requirements are more detailed than Part 820 for design changes — requiring documented impact assessments and verification of changes against specifications
• Supplier control: ISO 13485 Clause 7.4 has specific documented requirements for supplier evaluation, selection, and monitoring that extend beyond the previous Part 820 language

ETQ Reliance’s configurable application architecture allows organizations to build QMSR-compliant workflows across each of these areas. The Design and Development module addresses ISO 13485 Clause 7.3 change control. The Supplier Quality module covers ISO 13485 Clause 7.4. CAPA addresses Clause 8.5. Document Control covers Clause 4.2. For organizations migrating from a Part 820-only QMS to QMSR compliance, ETQ Reliance’s configuration flexibility allows the addition of ISO 13485-specific workflow elements to existing processes rather than requiring a platform replacement.

ETQ Reliance vs. MasterControl — When Does Each Apply?

The comparison between ETQ Reliance and MasterControl appears in almost every enterprise pharmaceutical QMS evaluation. Both are Gartner Magic Quadrant Leaders. Both serve heavily regulated industries with 21 CFR Part 11 and ISO 13485 requirements. The differentiation is architectural and organizational-model dependent.

The selection logic: ETQ Reliance is the stronger choice when configuration flexibility across industries and sites is the primary requirement, when the quality team wants to own the configuration without IT dependency, and when the CCU licensing model fits the workforce structure. MasterControl is the stronger choice when deep life sciences-specific workflow — integrated document lifecycle, training, and manufacturing execution in pharma — is the primary requirement.

For EHS quality integration alongside quality management, see our profiles on Intelex (EHSQ) and Cority (occupational health + quality). For pharmaceutical GMP context including EHS compliance, see our ISO 45001 implementation guide.

What Is the ETQ to Octave Rebrand — and What Does It Mean for Buyers?

Hexagon acquired ETQ in 2022. In 2026, Hexagon announced the planned spin-off of ETQ into an independent entity to be named Octave, with completion expected in H1 2026. The rebranding introduces Octave Reliance as the new product name — replacing ETQ Reliance — while maintaining the same software, the same support infrastructure, and the same development roadmap.

For buyers evaluating the platform in mid-2026, the practical implications are:

• The platform is functionally identical to ETQ Reliance — the rebrand is naming and corporate entity, not product
• Reliance AI (launched January 2026) and ETQ Reliance Go (launched December 2025 — a simplified eQMS for small-to-mid-sized manufacturers) remain part of the Octave portfolio
• Multi-year contracts should specify the new entity (Octave) as the contracting party and confirm SLA continuity through the transition
• Search queries for “ETQ Reliance” and “Octave Reliance” both refer to the same platform — buyers researching either name are looking at the same software

Who Should Not Buy ETQ Reliance?

Small manufacturers under 500 employees or $200M revenue without dedicated quality IT resources should evaluate ETQ Reliance Go — the simplified eQMS launched December 2025 specifically for small-to-mid-sized manufacturers — or lighter-weight alternatives like Qualio (optimized for growth-stage life sciences companies) before committing to the full ETQ Reliance platform’s implementation complexity and enterprise pricing.

Organizations whose primary compliance obligation is EHS management — ISO 45001, OSHA PSM, industrial hygiene programs — rather than quality management system compliance should evaluate Intelex, VelocityEHS, or Cority. ETQ Reliance has EHS modules, but EHS is not its core design architecture.

Organizations needing a rapidly deployable QMS without configuration investment — growth-stage biotech or startup medical device companies that need to be GMP-compliant in 90 days with minimal internal quality IT resources — will find Qualio or SimplerQMS faster to deploy with less organizational overhead than ETQ Reliance’s configuration-first model requires.

The Verdict on ETQ Reliance

ETQ Reliance — transitioning to Octave Reliance — is the enterprise QMS for regulated manufacturers that need configuration flexibility across the full quality management scope at multi-site, multi-industry scale. The 2026 Gartner Magic Quadrant Leader position, the QMSR-aligned architecture, Reliance AI’s quality intelligence layer, and 30+ years of regulated manufacturing QMS expertise are the platform’s evidence. The implementation complexity and the UI learning curve are the constraints that determine fit.

For pharmaceutical and medical device manufacturers whose QMS will face FDA inspections, EU Notified Body audits, and QMSR compliance requirements — and who have the implementation budget and organizational capacity to configure the platform correctly — ETQ Reliance offers a depth and flexibility of quality management infrastructure that few competitors match. For organizations that cannot absorb the configuration investment, the lighter-weight alternatives serve the compliance requirement at lower implementation cost.